Get the content you want anytime you want.
The Best Infectious Disease News Delivered Weekly

The Contagion® HCV / Hepatitis specialty page provides HCV / hepatitis-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


Exploring the Road to HIV-HCV Eradication in the DAA Era
Researchers posit that increased direct-acting antiviral (DAA) coverage can work to completely eradicate hepatitis c virus (HCV) in some populations of HIV-positive coinfected patients.
Hepatitis C and the Dwindling of Research Funding
Hepatitis C virus is the world’s most prevalent blood-borne viral infection for which a vaccine does not exist. To eliminate HCV infection on a global scale, experts argue that vaccine development needs to become a public health priority.
HCV Testing Remains Low Among High-Risk Population
When the US Preventive Services Task Force (USPSTF) recommended that all baby boomers undergo a one-time hepatitis C screening in 2013, testing prevalence increased. However, the rate is still lower than officials would like to see.
Egyptian Initiative Aims to Create “A World Free of Hepatitis C”
According to Tour n’ Cure, an Egyptian initiative that aims to rid the world of hepatitis C, Egypt aims to give program participants an opportunity to receive full treatment at an extremely low cost, while touring “the land that gave birth to the first great civilization.”
NSF Grant Funds Research to Better Predict Infectious Disease Outbreaks
Penn State researchers have been granted $2.35 million to go towards finding a way of better predicting infectious disease outbreaks.
Evaluating the Use of Anticoagulants in Patients with Advanced Liver Disease
Should practitioners administer these drugs to patients with advanced liver disease, despite the risks?
Top 5 <i>Contagion</i>® News Articles for the Week of February 26, 2017
Did you read this week’s top infectious disease news coverage from Contagion®?
Merck Loses Big Money on HCV Drug
Kenilworth, New Jersey-based Merck, will take a loss of $0.22 a share from last year’s fourth quarter. This will account for a total loss of $2.9 billion, or $1.9 billion after taxes. The pharmaceutical giant had previously reported a profit of $0.42 a share for that period.